| INTRODUC TI ON
Dysplastic naevi (DN) are intermediate melanocytic lesions that are important to distinguish from common melanocytic naevi (CMN) given their associated increased malignant melanoma (MM) risk. [1] Although no definitive clinical criteria for DN exist, they generally contain some of the following features: ≥5 mm, variable pigmentation, indistinct or irregular borders, and asymmetry. [1, 2] Histologically, DN are distinguished from CMN by architectural disorder and cytological atypia. [3, 4] DN can be further graded with mild, moderate or severe atypia, which correlates with increased melanoma risk. [5] MM contains increased severity and uniformity of atypical cells and demonstrates dermal invasion. [3, 4] Uncertainty remains around the progressive nature and the relationship between DN and melanoma. Proposed in 1984, the Clark model of melanoma development described the malignant transformation of CMN as occurring through a linear, stepwise series of mutations, with intermediate precursors. [6] Current understandings of MM formation support the idea of multiple trajectories towards oncogenesis, with the majority of lesions never progressing to malignancy. [7] [8] [9] Rendering support for distinct evolutionary lineages, genetic sequencing of driver mutations has revealed that most CMN have BRAFV600E mutations, while only some DN contain BRAFV600E mutations and other DN contain alternative oncogenic mutations, including BRAF non-V600E and NRAS mutations. [8] Clinically, the presence of a single DN confers a twofold increased risk of MM compared to no increased risk from a CMN. [1] Relative to CMN and MM, DN exhibit intermediate levels of cellular proliferation [10, 11] and point-mutational burden, upregulation of telomere maintenance mechanisms (TMMs) and heterozygous loss of CDKN2A function. [8] Telomerase reverse transcriptase promoter mutations (TPMs) are common somatic, noncoding mutations that occur in many cancers, including melanoma. [12] [13] [14] In a gene sequencing study of melanocytic lesions, 77% of DN and melanoma in situ contained TPMs, [8] which contribute to genomic instability and allow for additional time for cellular replication and associated mutations and the development of functional TMMs to bypass replicative senescence and achieve cellular immortalization. [12, 15] However, an estimated equal percentage of 20-50% of melanomas arise adjacent to CMN or DN, [16, 17] arguing against an increased risk of MM development from DN. Thus, there is still debate about the progressive nature and oncogenic potential of DN, particularly in comparison with CMN. [7, 8, 16] In this study, we investigated the relationship between CMN, DN and MM using differential gene expression and pathway analyses.
Our findings posit the DN as a lesion exhibiting intermediary molecular behaviours and activation of pathways implicated in melanoma development. Moreover, we further characterize the immune microenvironment of the three classes of melanocytic lesions and find that increased negative immunoregulatory molecules, immune checkpoints and dysfunctional, exhausted immune cell types characterize the immune progression from CMN to DN to MM.
| MATERIAL S AND ME THODS

| Patient enrolment and tissue samples
This is an institutional review board-approved study with written informed consent obtained prior to patient enrolment. The study was performed in accordance with the Declaration of Helsinki Principles.
Whole tissue samples were obtained via excisional biopsies at the Rockefeller University, Charite University and Tel-Hashomer
Hospital. The biopsies were bisected with one half processed in formalin for routine haematoxylin and eosin staining and pathological diagnosis and the other half was frozen in OCT compound for RNA and immunohistochemistry analysis. Tissue was never destroyed en bloc in the event that the pathologist thought diagnostic information was needed from the frozen sections. As described in our previous study, [11] DN were classified by an experienced dermatopathologist using cytological and architectural features. [4] Melanocytic nuclear atypia was noted if irregular, hyperchromatic or with prominent nucleoli. Architectural disorder included elongation and bridging of rete ridges and the "shoulder" phenomenon. [4] Table S1 .
| RNA extraction
Total RNA extraction was performed from frozen tissue sections using the RNeasy Micro Kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol.
| cDNA microarray analysis
Target amplification and labelling to the Human Genome U133 2.0 plus arrays were performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). The data can be found at the Gene Expression Omnibus repository (GSE accession number GSE114445).
| Quantitative RT-PCR
Manufacturer's instructions (Applied Biosystems, Foster City, CA)
were followed for preamplification and mRNA expression measurements. Data were normalized to RPLP0/hARP. The primers and probes used are listed in Table S2 .
| Immunohistochemistry and immunofluorescence
Frozen skin sections were prepared, and standard protocol was followed. Antibodies used are listed in Table S2 .
| Statistical analyses
Microarray analyses were performed in R/Bioconductor packages. Table S3 ). Further pathway analysis was performed using the Ingenuity Pathway Analysis Tool (Ingenuity H Systems, Redwood City, CA). Gene-based enrichment analysis was conducted via eXploring Genomic Relations (XGR). (NRML), among the most highly expressed genes in both lesions were involved in pigmentation, including TYR, TRPM1, GPR143, MLANA and SLC45A2 (Table 1) . A study from 2017 found 4,638 differentially expressed genes (DEGs) between CMN and MM using RNA sequencing. [18] In our microarray analysis, there were 2687 DEGs (fold change, FCH ≥1.5 or ≤−1.5; false discovery rate, FDR ≤0.10) between CMN and MM, with an overlap of 1336 DEGs (49.7%) compared to the aforementioned study ( Figure S1A ). Gene-based enrichment analysis of these 1336 DEGs indicated that the major biological processes enriched in both data sets included innate immune response, IFN-gamma signalling (T-helper type 1 response), cell adhesion, angiogenesis and apoptosis. Of known cancer-associated antigens, both methods showed high expression levels of PRAME (preferentially expressed antigen in melanoma), but MAGE (melanoma-associated antigen) isoforms were detected only by microarray and also confirmed by RT-PCR (data presented later in Figure 2 ). Analysis of the 1351 DEGs uniquely present in our data set revealed that the major biological processes enriched included stem cell division, vesicular trafficking, keratinocyte development and epigenetic modifications ( Figure S1B ). Contrasting with the data from the Badal et al.
report, [18] we did not detect enrichment for the biological processes
of translation regulation, IL-4 activity (T-helper type 2 polarization)
and cytokinesis that were detected in 3302 unique genes from the RNA sequencing analysis ( Figure S1C ). Given differences in immune activity detected in this study versus the Badal et al. report [18] and that neither RNA sequencing nor gene arrays have sufficient sensitivity for quantification of priming cytokines of polar T-cell subsets,
we used more sensitive RT-PCR to measure T-cell subset activity in these melanocytic growths, as detailed later in results.
| Naevi and melanoma have distinct gene expression profiles versus normal skin
To our knowledge, previous studies have not incorporated the com- teins. [11] Thus, we focused our analysis on molecular differences and similarities between DN and MM.
| Differences in immune system activation distinguish the DN and MM transcriptomes
To better understand the relationship between DN and MM, we directly compared their GEPs ( Figure 1D ). There were 70 genes contained within both GEPs that were not differentially expressed. In other words, these 70 genes account for the similar ways in which Figure S3A ).
In our analysis, there were several sets of genes that were not differentially expressed between MM and DN and also were not differentially expressed either between MM and NRML or DN and NRML. There were 8 genes within the DN GEP that were not differentially expressed between DN and MM or between MM and NRML (LOC284513, DBN1, TP73-AS1, SLC17A5, MEF2D, ENTPD1, POLR1E and WDR63), suggesting that these genes have intermediate expression levels in MM without meeting our criteria for DEGs.
Of note, TP73-AS1 has been reported to have tumor-suppressive properties in melanoma. [22] There were 3755 genes within the MM GEP that were not differentially expressed between MM and DN or between DN and NRML, suggesting that DN may display intermediate expression levels of these genes without meeting our criteria for DEGs. Analysis of the 3755 genes revealed enrichment for biological processes including neutrophil degranulation, regulation of Rho protein signal transduction, negative regulation of T-cell receptor signalling, cell proliferation and apoptosis ( Figure S3B ).
| DN display intermediate expression levels of molecular gene signatures implicated in melanoma
Given that DN clustered in an intermediary position in the PCA plot ( Figure 1B) , we investigated the underlying molecular behaviour and changes in pathway activation in the three melanocytic lesions. An unbiased analysis of molecular gene signatures implicated in oncogenesis and melanoma was curated from the literature and the Broad Institute, as listed in Table S3 . [23] [24] [25] [26] [27] Progressive increases in cell proliferation pathways from CMN to DN to MM, with statistically significant and prominent fold changes in MM (Figure 2A ), were observed.
Similarly, progressive increases were found in other pathways implicated in oncogenesis, including epithelial-to-mesenchymal transition (EMT), metabolic reprogramming (upregulation in glycolysis), apoptosis and immunoregulation. Pathways expressed to a similar degree in DN and MM included hypoxia and angiogenesis. Additionally, genes upregulated as a response to ultraviolet (UV) irradiation and in CD271+ cells, which are melanoma-initiating cells [28] associated with increased tissue invasion, [23] were also statistically and progressively increased. To investigate for differences in the cell cycle check-
points, genes involved in the progression through G1/S (E2F targets)
and the G2/M checkpoint pathways were queried, with significant F I G U R E 2 Dysplastic naevi demonstrate intermediate molecular cell behaviours and pathways, with immune progression from common naevi to dysplastic naevi to melanoma. Log 2 fold change (Log 2 FCH) least squares mean of common melanocytic naevi (CMN), dysplastic naevi (DN) and malignant melanoma (MM) versus normal skin (NRML) for differentially expressed genes in various gene expression signatures of molecular pathways and behaviours implicated in cancer demonstrating progressive changes (A) and nonprogressive changes (B) with statistically significant differences between groups indicated by a * located under the group being compared to another lesional category as specified by the corresponding star colour. (C) Immunohistochemistry of CD3+ and CD11c+ infiltrates in the lesions. Scale bar = 100 μm. RT-PCR of cytokines from Th1, Th2 and Th17 immune axes (D-H) and melanoma-associated antigens (I-K) with fold changes ± standard error of the mean (SEM) and * indicating statistically significant differences. Increasing number of stars indicates greater statistical significance, with *P < 0.05, **P < 0.01 and ***P < 0.001 changes between MM and the other two lesions observed. Lastly, cell signalling pathways implicated in MM development, including
MAPK/KRAS/MEK, PI-3K/AKT/mTOR/PTEN and Hedgehog, were
examined. [29, 30] Of these pathways, MAPK/KRAS/MEK, PI-3K/AKT/ mTOR and Hedgehog signalling revealed progressive increases in activation. Clear progressive changes in Notch, Myc, p53 and Wnt/β-catenin pathways were not appreciated ( Figure 2B ).
| Progressive increases in mitogenic cytokines and melanogenic growth factors from CMN to DN to MM
Given the prominent increase in the cell proliferation gene signature in MM relative to the benign lesions, an investigation into growth factors and receptors was conducted. By RT-PCR, an increasing trend in the chemokine CXCL1 and its receptor CXCR2 was found ( Figure S4A ,B). CXCL1 and CXCR2 are involved in an autocrine growth factor loop in melanoma cells and proliferating melanocytes. [31] Increases in IL-6 and IL-8, cytokines involved in melanoma cell growth, [32] [33] [34] [35] [36] were also appreciated ( Figure S4C,D) . Similarly, OSM, an IL-6 family cytokine, was progressively increased from CMN to DN to MM ( Figure S4E ). NGF, GM-CSF, VEGFA and PDGFB also displayed increased levels in MM (Figure S4F-I ).
| Immune progression from CMN to DN to MM
With the significant immune activity and immunoregulation ob- and PRAME, was performed, which revealed progressive increases, though the expression was quantitatively much larger between DN and MM ( Figure 2I-K) .
| Progressive increases in dysfunctional, immunosuppressive immune cells from CMN to DN to MM
Given evidence of a decreased Th1 or Tc1 immune response in MM and progressive increases in melanoma-associated antigens, we examined if immunoregulatory and/or tolerogenic immune cells were similarly progressively increased. Recent literature has shown that the presence of increased lymphocytic infiltrates in MM alone may not be as significant as the functional activity of these cells in combating MM. [37] Thus, we queried immune cell-specific gene transcript signatures, [38] [39] [40] [41] 
| SOCS3 is upregulated in dendritic cells in MM and presents a potential alternative immunotherapeutic avenue
With increased expression of multiple molecules associated with tolerogenic DCs in MM, we performed IHC staining for SOCS3, a marker of tolerogenic DCs. [42, 43] Compared with NRML, which displayed rare SOCS3+ DCs, MM displayed prominent SOCS3 staining in a DC pattern ( Figure 4A ). Double immunofluorescence confirmed increased CD11c+ DC expression of SOCS3 in MM, but only rare expression of SOCS3+ DCs in NRML ( Figure 4B ). Comparing the expression levels between MM and NRML, we found similarities in the consistency of upregulated SOCS3 expression across samples compared to current immunotherapeutic targets, including CTLA4
and CD274 (no statistically significant differences in proportions), as shown in Figure 4C . In contrast, compared to CTLA4, there was heterogeneity of expression levels in MM for MAGE-A3 (P = 0.02)
and MAGE-A6 (P = 0.04). Given the immunosuppressive properties 
| D ISCUSS I ON
In this study, we elucidated the molecular and cellular characteristics of DN, along with its relationship with respect to CMN and MM, using a rigorous statistical method that has previously been successfully applied to the study of many cutaneous diseases, including psoriasis, [27, 44, 45] alopecia areata, [46] atopic dermatitis [47] [48] [49] and skin cancers. [50, 51] Studies investigating the molecular profiles of melanocytic lesions that include DN are limited. In the only previous study that directly compared DN and MM, gene transcripts in the DN were found to differ from that of melanoma in the regulation of transcription and the mismatch repair system. [52] Similarly, in our study, we ing the capacity to invade and metastasize, reprogramming cellular metabolism and escaping immune surveillance. [53] The hallmarks of cancer have been criticized as a framework for understanding oncogenesis given that invasion and metastasis is the only one of the original six hallmarks that are not also characteristic of benign tumors. [54] However, the increasing trend in gene signatures associated with tis- Boxed samples indicate upregulation in MM, with expression levels higher than the 95% confidence interval for normal tissue for the corresponding gene. Bar with P-value indicates statistically significant differences in the proportion of MM samples with upregulated expression levels compared to NRML. Scale bar = 100 μm Th17 immune axes. Indeed, a significantly increased ratio of DEGs in the pathogenesis of multiple sclerosis pathway was appreciated.
Lending support to our findings, multiple sclerosis is an autoimmune demyelinating disease that is associated with alterations in Th1/ Th2/Th17 cells. [55] [56] [57] From our results, we hypothesized that similar to the immune clearance that tempers the oncogenic transformation of premalignant, senescent hepatocytes, [58] somatic mutations in neoplastic melanocytes can lead to the expression of antigens which stimulate immune system activation and clearance. It has been proposed that cellular proliferation in the DN is balanced by cellular attrition factors, including immunosurveillance. [7] MM would therefore represent a disruption in the balance between immunosurveillance and neoplastic cell transformation and proliferation. Indeed, we found that DN and MM microenvironments displayed progressively increased levels of negative immunoregulation.
In accordance with the increased immunosuppressive landscape in melanoma, our study identified increased DCs expressing suppressive markers that have previously been associated with tolerogenic, immunoregulatory function. Similar to SOCS2, which was previously identified as a protein expressed by dendritic cells that is critical for limiting antitumor immune response in MM, [59] SOCS3 is also a member of the suppressor of cytokine signalling (SOCS) proteins family.
SOCS3 expression by dendritic cells has not previously been described in human melanoma. Increased cytokine IL-10 in the immune microenvironment has been reported to increase SOCS3 expression and IL-10 secretion by DCs, which prolong Treg cell function. [40] Treg cells, in turn, contribute to T-cell exhaustion, [60] which mount ineffective immune responses against cancer. SOCS3+ DCs also direct T-cell polarization towards a Th2 phenotype. [42, 61] Additionally, T-cell effector responses can be hampered by tolerogenic DCs, as antigen presentation in SOCS3+ DCs is disrupted in tumors, [62] with lower expression of MHC class II and costimulatory molecules. [42] SOCS3
in tumor-associated DCs can also inhibit the activation of DCs from type I IFN signalling. [63] The increase in immunosuppressive and ex- 
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